Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots
Executive Summary
Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's
You may also be interested in...
As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says
The Irish company is still dealing with the after-effects of splitting apart its business in 2011, including its search for a new CEO. Meanwhile, Elan’s lead revenue driver, Tysabri continues to grow.
New Cambridge-Elan Centre To Focus On Alzheimer's With $10 Million From Elan
Ireland's Elan Corp. launches a $10 million center for neuroscience R&D with University of Cambridge academics.
J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets
Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion